Where Will Summit Therapeutics Be in 3 Years?

There's a lot riding on how its collaborator's studies end up performing. Believe it or not, it's entirely possible to build out a successful biopharma without actually doing much (or any) work in the laboratory. And, at least for now, that's exactly what Summit Therapeutics (SMMT -2.79%) is angling to do. Thanks to its collaboration with a highly capable company abroad, this biotech may soon demonstrate the powerful financial performance that's possible using an asset-light business model. With that frame ...